Posts by author
Marc Beishon
Liver cancer: how Europe can halt the rising death toll
When the cancer community in Europe talks of neglected cancers it usually means relatively rare or uncommon types, of which there are many. But conspicuous in the list are two digestive cancers that are both deadly, not uncommon and increasing…
Trust me: I’m a surgical oncologist!
Surgery has been the mainstay for treating solid tumours since the dawn of cancer treatment, and recent decades have seen a huge increase in the complexity and multidisciplinary demands of carrying out cancer operations. So it can come as a…
Mike Morrissey: At your service
The European cancer community has long had its ups and downs in its efforts to act in concert to promote policy and standards throughout its constituent countries, which differ widely in their healthcare systems and resources. There have been numerous…
José Baselga: A giant of medical oncology
José Baselga, one of the most high profile oncologists of recent times, has died at the age of 61. His fame in the cancer world is confirmed by the volume of tributes on social media and websites globally, and in…
Immunotherapy toxicities demand a joined up approach from oncologists and organ specialists
Adverse effects of cancer therapies have long been at the root of decision making for interventions in all modalities – surgery, radiotherapy and medical – and especially in the latter category of anti-cancer drugs. Most people have heard of some…
EMA at 25: learning more from cancer patients
Responsibility for scientific evaluation, supervision and safety monitoring of medicines was done at the national level until 1995, when EU member states agreed to coordinate that work within the European Medicines Agency (EMA). A quarter of a century on, and…
Rapid palliation of bone mets: it’s effective and easy, so why aren’t we all doing it?
Bone metastases occur in around 7 out of every 10 people with advanced cancer, and are most frequently found in people with breast, prostate, lung or kidney cancers, and in most people with advanced multiple myeloma. They cause pain and…
Could covid-19 boost interest in drug repurposing in oncology?
Could the frantic search for drugs to treat patients severely affected by the covid-19 virus be a shot in the arm for new cancer treatments? There have been many headlines about repurposed agents, such as the highly debated antimalarial drug…
Karen Benn: a great example of what an advocate can accomplish
Tributes have poured in for Karen Benn, deputy CEO and head of public affairs at Europa Donna, who died on 4 September. Karen was one of the longest serving officers at Europa Donna, the European Breast Cancer Coalition that unites…
Does it work for my patient? A pragmatic approach to building evidence on clinical effectiveness
Should patients be at the centre of attention in the development of new cancer drugs? It might seem extraordinary that this question is even asked – what else matters? But it is a question high on the agenda of the…